RedHill Biopharma Ltd. (NASDAQ:RDHL) Short Interest Down 43.6% in January

RedHill Biopharma Ltd. (NASDAQ:RDHL) saw a large decline in short interest in January. As of January 31st, there was short interest totalling 5,300 shares, a decline of 43.6% from the January 15th total of 9,400 shares. Based on an average daily volume of 15,600 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.4% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on shares of RedHill Biopharma in a report on Sunday. They set a “hold” rating for the company.

RedHill Biopharma Trading Down 7.1 %

Shares of RDHL traded down $0.40 during mid-day trading on Thursday, reaching $5.20. 6,045 shares of the stock traded hands, compared to its average volume of 10,155. RedHill Biopharma has a 12-month low of $5.20 and a 12-month high of $20.27. The stock has a fifty day simple moving average of $6.36 and a 200 day simple moving average of $36.25.

Institutional Trading of RedHill Biopharma

A hedge fund recently bought a new stake in RedHill Biopharma stock. GAMMA Investing LLC bought a new position in RedHill Biopharma Ltd. (NASDAQ:RDHL) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 5,089 shares of the biotechnology company’s stock, valued at approximately $32,000. GAMMA Investing LLC owned about 0.40% of RedHill Biopharma as of its most recent SEC filing. Hedge funds and other institutional investors own 7.20% of the company’s stock.

RedHill Biopharma Company Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.